Abstract
This paper reviews Bayesian dose-escalation procedures for phase 1 clinical trials and describes a systematic approach to their implementation. The methodology is constructed for studies in which each subject is administered a single dose of an experimental drug and provides a single binary response, referred to here as toxicity or no toxicity. It is assumed that the probability of toxicity rises with log dose of drug according to a logistic regression model.
It is suggested that the choice of suitable prior distributions be aided via graphical representations of their properties and simulation investigations of their consequences. Possible safety constraints and stopping rules are described. Given this information, the recommended doses for the first cohort of subjects can be computed. Once their responses become available, subjective distributions can be updated, and the recommended doses for the second cohort can be determined. The procedure continues in this way until a stopping rule is reached, or until some maximum number of subjects has been observed. Clinical investigators are free to overrule the doses recommended by the procedure and to substitute those that they feel are more appropriate.
Similar content being viewed by others
References
Whitehead J, Brunier H. Bayesian decision procedures for dose determining experiments. Stat Med. 1995;14:885–893.
Whitehead J. Williamson D. An evaluation of Bayesian decision procedures for dose-finding Studies. J Biopharma Stat. 1998;8:445–467.
Judson IR. Evaluation of new anticancer drugs. In Horwich A, ed. Oncology: Multidisciplinary Textbook. London, United Kingdom: Chapman and Hall; 1995:147–159.
Carter SK. Study design principles in the clinical evaluation of new drugs as developed by the chemotherapy programme of the National Cancer Institute. In: Staquet MJ. ed. The Design of Clinical Trials in Cancer Therapy. Brussels, Belgium: Editions Scientific Europe; 1973: 242–289.
Whitehead J. Bayesian decision procedures with application to dose-finding studies. Int J Pharma Med. 1997;11:201–208.
Lin Y. Shih WJ. Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics. 2001;2:203–215.
O’Quigley J, Pepe M, Fisher L. Continual Reassessment Method: a practical design for phase I clinical trials in cancer. Biometrics. 1990:46:33–48.
Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, and Simon RM. A comparison of two phase I designs. Stat Med. 1994;13: 1799–1806.
Faries D. Practical modifications of the continual reassessment method for phase I cancer clinical trials. J Biopharma Stat. 1994;4:147–164.s
Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med. 1995;14:1149–1161.
O’Quigley J, Shen LZ. Continual reassessment method: a likelihood approach. Biometrics. 1996; 52:673–684.
O’Quigley J. Dose-finding design using continual reassessment method. In: Crowley. J. ed. Handbook of Statistics in Clinical Oncology. New York, NY: Dekker; 2001:35-72.
Heyd JM, Carlin BP. Adaptive design improvements in the continual reassessment method for phase I studies. Slat Med. 1999; 18:1507–1321.
O’Quigley J, Reiner E. A stopping rule for the continual reassessment method. Biometrika. 1998;85:741–748.
O’Quigley J. Continual reassessment designs with early termination. Biostatistics. 2002;3: 87–99.
Ferry DR, Smith A, Malkhandi J, Fyfe DW, de-Takats PG, Anderson D, Baker J, Kerr DJ. Phase I clinical trial of the flavonoid quercetin—pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Research. 1996; 2:659-668.
Piantadosi S, Liu G. Improved designs for dose escalation studies using pharmacokinetic measurements. Stat Med. 1996;15:1605–1618.
Wang O, Faries DE. A two-stage dose selection strategy in phase I trials with wide dose ranges. J Biopharma Stat. 2000;10:319–333.
Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med. 1998;17:1103–1120.
Casparini M, Eisele J. A curve-free method for phase I clinical trials. Biometrics. 2000;56: 609–615.
Zhou Y, Whitehead J. Bayesian ADEPT: Operating Manual. Reading, United Kingdom: The University of Reading; 2002.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zhou, Y., Whitehead, J. Practical Implementation of Bayesian Dose-Escalation Procedures. Ther Innov Regul Sci 37, 45–59 (2003). https://doi.org/10.1177/009286150303700108
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286150303700108